Drug Profile
Research programme: respiratory disease therapeutics - Almirall/BioFocus
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Almirall S.A.; BioFocus DPI
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Respiratory-tract-disorders in Europe
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 27 Jan 2012 Early research in Respiratory tract disorders in Europe (unspecified route)